RxDoctor Payments Data

David Miller, PA

Physician Assistant · Stanford, CANPI 1538140413

Payments from drug & device makers

$2,602in general payments, 2019–2025

Across 121 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$441
  • Merck$271
  • Novartis$240
  • AstraZeneca$216
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$208
  • Pfizer$159
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,49296%
  • Education$1104%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,602 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$132,247
Medicare patients
537
Services billed
1,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$142,217
CreonLipase/Protease/Amylase18$57,750
EntrestoSacubitril/Valsartan46$41,773
XareltoRivaroxaban36$34,802
MultaqDronedarone Hcl13$22,779
JardianceEmpagliflozin23$14,818
BrilintaTicagrelor11$5,547
Dabigatran EtexilateDabigatran Etexilate Mesylate14$2,171
Ranolazine ErRanolazine25$1,669
Ezetimibe40$1,632
Atorvastatin Calcium177$1,483
Metoprolol Succinate115$1,357
Propafenone Hcl14$1,104
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide22$1,054
Carvedilol116$1,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$142,217134 claims
NovartisEntresto$240$41,77346 claims
Johnson & JohnsonXarelto$70$34,80236 claims
Sanofi-aventis U.S. LLCMultaq$41$22,77913 claims
Boehringer IngelheimJardiance$62$14,81823 claims
AstraZenecaBrilinta$216$5,54711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →